In conversation with Dr. Simon Pimstone

As CEO of Xenon Pharmaceuticals, Dr. Simon Pimstone and his partners have led the closely held Vancouver company on a journey of developing novel drugs that target genetically defined targets.  By studying genes responsible for rare and inherited diseases, Xenon figures they represent highly validated intervention points for new medicines.  In other words, going from [...]

Protected: Protox gets credibility boost from Warburg Pincus

There is no excerpt because this is a protected post.

Merck cancer vaccine a priority for Immunovaccine

Immunovaccine (TSX-V:IMV) is making a new clinical-stage cancer vaccine that it acquired from Germany’s Merck KGaA in June a development and regulatory priority as it formulates Merck’s survivin-based vaccine with its own DepoVax delivery system. “The reason we’re excited about it is that the National Cancer Institute ranks survivin as one of the top 25 [...]

Tekmira and Pfizer in research collaboration

Tekmira Pharmaceuticals (TSX:TKM) has initiated a new research collaboration with Pfizer to evaluate Tekmira’s stable nucleic acid-lipid particle (SNALP) technology to deliver small interfering RNA molecules provided by Pfizer (NYSE:PFE). This is Tekmira’s first formal research collaboration with Pfizer. Tekmira will be responsible for preparing the SNALP formulations and Pfizer will evaluate the formulations in [...]

« Previous Page